Yale Pulmonary Critical Care and Sleep Medicine Grand Rounds

Presented by
Yale School of Medicine, Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine

Year in Review - Interstitial Lung Disease

Danielle Antin-Ozerkis, MD
Associate Professor of Medicine, Pulmonary
Medical Director, Yale ILD Center of Excellence
Yale School of Medicine

Jan Fouad, MD
Fellow, Pulmonary and Critical Care Medicine
Yale School of Medicine

Wednesday, June 9, 2021 @ 3-4 pm EDT

REMOTE ATTENDANCE ONLY – NO LOCAL AUDIENCE

Register at: https://zoom.us/meeting/register/tJAoc2upzMtHt2dAPXNBWZ_Ek6wGMaOJDn4

Only need to register once for the series

CME credit for live event only.
There is no corporate support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

NEEDS ASSESSMENT
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal form of interstitial lung disease (ILD) and is important to recognize, accurately diagnose and treat. Guidelines for the diagnostic criteria of IPF and other forms of ILD have changed and misdiagnosis and delayed diagnosis are common. Studies have shown that when non-expert physicians discuss IPF cases, diagnostic accuracy improves. This talk will help listeners understand how to diagnose and treat IPF and other forms of ILD. New guidelines will be reviewed and recent treatment advances will be discussed. References include: Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline American Journal of Respiratory and Critical Care Medicine Volume 198 Number 5, September 1 2018. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities Lancet Respir Med. 2020 Sep;8(9):925-934. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med Vol 202, Iss 3, pp e366-e69, Aug 1, 2020Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. Expert Opin Emerg Drugs. 2021 May 24;1-9.

LEARNING OBJECTIVES
At the conclusion of this talk, individuals will:
1. Learners will be able to use ATS guidelines to determine a diagnosis of IPF.
2. Learners will understand the role of newer technologies such as cryobiopsy and genomic classifier in the diagnosis of IPF.
3. Learners will be able to describe the role of antifibrotic therapy in ILD.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Richard Matthay, MD, Course Director – No conflicts of interest
Danielle Antin-Ozerkis, MD – Boehringer Ingelheim, Fibrogen, Pliant, Galecto, Galapagos, Genentech/Roche
Jan Fouad, MD – No conflicts of interest

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.